لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Babbe H; Janssen Research and Development, LLC., Spring House, PA 19477., Sundberg TB; Broad Institute of MIT and Harvard, Center for the Development of Therapeutics, Cambridge, MA 02142., Tichenor M; Janssen Research and Development, LLC., San Diego, CA 92121., Seierstad M; Janssen Research and Development, LLC., San Diego, CA 92121., Bacani G; Janssen Research and Development, LLC., San Diego, CA 92121., Berstler J; Broad Institute of MIT and Harvard, Center for the Development of Therapeutics, Cambridge, MA 02142., Chai W; Janssen Research and Development, LLC., San Diego, CA 92121., Chang L; Janssen Research and Development, LLC., San Diego, CA 92121., Chung M; Janssen Research and Development, LLC., San Diego, CA 92121., Coe K; Janssen Research and Development, LLC., San Diego, CA 92121., Collins B; Janssen Research and Development, LLC., San Diego, CA 92121., Finley M; Janssen Research and Development, LLC., Spring House, PA 19477., Guletsky A; Broad Institute of MIT and Harvard, Center for the Development of Therapeutics, Cambridge, MA 02142., Lemke CT; Broad Institute of MIT and Harvard, Center for the Development of Therapeutics, Cambridge, MA 02142., Mak PA; Janssen Research and Development, LLC., San Diego, CA 92121., Mathur A; Janssen Research and Development, LLC., Spring House, PA 19477., Mercado-Marin EV; Janssen Research and Development, LLC., San Diego, CA 92121., Metkar S; Broad Institute of MIT and Harvard, Center for the Development of Therapeutics, Cambridge, MA 02142., Raymond DD; Broad Institute of MIT and Harvard, Center for the Development of Therapeutics, Cambridge, MA 02142., Rives ML; Janssen Research and Development, LLC., San Diego, CA 92121., Rizzolio M; Janssen Research and Development, LLC., San Diego, CA 92121., Shaffer PL; Janssen Research and Development, LLC., Spring House, PA 19477., Smith R; Janssen Research and Development, LLC., San Diego, CA 92121., Smith J; Janssen Research and Development, LLC., San Diego, CA 92121., Steele R; Janssen Research and Development, LLC., Spring House, PA 19477., Steffens H; Janssen Research and Development, LLC., San Diego, CA 92121., Suarez J; Janssen Research and Development, LLC., Spring House, PA 19477., Tian G; Janssen Research and Development, LLC., Spring House, PA 19477., Majewski N; Janssen Research and Development, LLC., Spring House, PA 19477., Volak LP; Janssen Research and Development, LLC., San Diego, CA 92121., Wei J; Janssen Research and Development, LLC., San Diego, CA 92121., Desai PT; Janssen Research and Development, LLC., Spring House, PA 19477., Ong LL; Janssen Research and Development, LLC., Spring House, PA 19477., Koudriakova T; Janssen Research and Development, LLC., San Diego, CA 92121., Goldberg SD; Janssen Research and Development, LLC., San Diego, CA 92121., Hirst G; Janssen Research and Development, LLC., San Diego, CA 92121., Kaushik VK; Broad Institute of MIT and Harvard, Center for the Development of Therapeutics, Cambridge, MA 02142., Ort T; Janssen Research and Development, LLC., Spring House, PA 19477., Seth N; Janssen Research and Development, LLC., Spring House, PA 19477., Graham DB; Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA 02114.; Department of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114.; Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA 02142., Plevy S; Janssen Research and Development, LLC., Spring House, PA 19477., Venable JD; Janssen Research and Development, LLC., San Diego, CA 92121., Xavier RJ; Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA 02114.; Department of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114.; Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA 02142., Towne JE; Janssen Research and Development, LLC., San Diego, CA 92121.

المصدر: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2024 Jan 02; Vol. 121 (1), pp. e2307086120. Date of Electronic Publication: 2023 Dec 26.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: National Academy of Sciences Country of Publication: United States NLM ID: 7505876 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1091-6490 (Electronic) Linking ISSN: 00278424 NLM ISO Abbreviation: Proc Natl Acad Sci U S A Subsets: MEDLINE

مواضيع طبية MeSH: Protein Serine-Threonine Kinases*/metabolism , Cyclic AMP Response Element-Binding Protein*/metabolism, Mice ; Humans ; Animals ; Cytokines ; Inflammation/drug therapy ; Protein Isoforms ; Anti-Inflammatory Agents/pharmacology ; Immunity, Innate ; Transcription Factors

المؤلفون: Volak LP; Janssen Research & Development, LLC, San Diego, California (L.P.V.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.M.D.); Amgen Inc, San Francisco, California (S.H.); Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (D.N.); AbbVie Inc, North Chicago, Illinois (C.P.); AstraZeneca, Cambridge, United Kingdom (A.P.); Roche pRED, Basel, Switzerland (C.R.); GlaxoSmithKline, Stevenage, United Kingdom (P.S.-S.); Genentech, San Francisco, California (D.Z.); and Takeda Development Center Americas, San Diego, California (M.Z.) lvolak@rapportrx.com., Duevel HM; Janssen Research & Development, LLC, San Diego, California (L.P.V.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.M.D.); Amgen Inc, San Francisco, California (S.H.); Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (D.N.); AbbVie Inc, North Chicago, Illinois (C.P.); AstraZeneca, Cambridge, United Kingdom (A.P.); Roche pRED, Basel, Switzerland (C.R.); GlaxoSmithKline, Stevenage, United Kingdom (P.S.-S.); Genentech, San Francisco, California (D.Z.); and Takeda Development Center Americas, San Diego, California (M.Z.)., Humphreys S; Janssen Research & Development, LLC, San Diego, California (L.P.V.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.M.D.); Amgen Inc, San Francisco, California (S.H.); Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (D.N.); AbbVie Inc, North Chicago, Illinois (C.P.); AstraZeneca, Cambridge, United Kingdom (A.P.); Roche pRED, Basel, Switzerland (C.R.); GlaxoSmithKline, Stevenage, United Kingdom (P.S.-S.); Genentech, San Francisco, California (D.Z.); and Takeda Development Center Americas, San Diego, California (M.Z.)., Nettleton D; Janssen Research & Development, LLC, San Diego, California (L.P.V.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.M.D.); Amgen Inc, San Francisco, California (S.H.); Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (D.N.); AbbVie Inc, North Chicago, Illinois (C.P.); AstraZeneca, Cambridge, United Kingdom (A.P.); Roche pRED, Basel, Switzerland (C.R.); GlaxoSmithKline, Stevenage, United Kingdom (P.S.-S.); Genentech, San Francisco, California (D.Z.); and Takeda Development Center Americas, San Diego, California (M.Z.)., Phipps C; Janssen Research & Development, LLC, San Diego, California (L.P.V.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.M.D.); Amgen Inc, San Francisco, California (S.H.); Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (D.N.); AbbVie Inc, North Chicago, Illinois (C.P.); AstraZeneca, Cambridge, United Kingdom (A.P.); Roche pRED, Basel, Switzerland (C.R.); GlaxoSmithKline, Stevenage, United Kingdom (P.S.-S.); Genentech, San Francisco, California (D.Z.); and Takeda Development Center Americas, San Diego, California (M.Z.)., Pike A; Janssen Research & Development, LLC, San Diego, California (L.P.V.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.M.D.); Amgen Inc, San Francisco, California (S.H.); Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (D.N.); AbbVie Inc, North Chicago, Illinois (C.P.); AstraZeneca, Cambridge, United Kingdom (A.P.); Roche pRED, Basel, Switzerland (C.R.); GlaxoSmithKline, Stevenage, United Kingdom (P.S.-S.); Genentech, San Francisco, California (D.Z.); and Takeda Development Center Americas, San Diego, California (M.Z.)., Rynn C; Janssen Research & Development, LLC, San Diego, California (L.P.V.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.M.D.); Amgen Inc, San Francisco, California (S.H.); Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (D.N.); AbbVie Inc, North Chicago, Illinois (C.P.); AstraZeneca, Cambridge, United Kingdom (A.P.); Roche pRED, Basel, Switzerland (C.R.); GlaxoSmithKline, Stevenage, United Kingdom (P.S.-S.); Genentech, San Francisco, California (D.Z.); and Takeda Development Center Americas, San Diego, California (M.Z.)., Scott-Stevens P; Janssen Research & Development, LLC, San Diego, California (L.P.V.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.M.D.); Amgen Inc, San Francisco, California (S.H.); Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (D.N.); AbbVie Inc, North Chicago, Illinois (C.P.); AstraZeneca, Cambridge, United Kingdom (A.P.); Roche pRED, Basel, Switzerland (C.R.); GlaxoSmithKline, Stevenage, United Kingdom (P.S.-S.); Genentech, San Francisco, California (D.Z.); and Takeda Development Center Americas, San Diego, California (M.Z.)., Zhang D; Janssen Research & Development, LLC, San Diego, California (L.P.V.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.M.D.); Amgen Inc, San Francisco, California (S.H.); Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (D.N.); AbbVie Inc, North Chicago, Illinois (C.P.); AstraZeneca, Cambridge, United Kingdom (A.P.); Roche pRED, Basel, Switzerland (C.R.); GlaxoSmithKline, Stevenage, United Kingdom (P.S.-S.); Genentech, San Francisco, California (D.Z.); and Takeda Development Center Americas, San Diego, California (M.Z.)., Zientek M; Janssen Research & Development, LLC, San Diego, California (L.P.V.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.M.D.); Amgen Inc, San Francisco, California (S.H.); Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (D.N.); AbbVie Inc, North Chicago, Illinois (C.P.); AstraZeneca, Cambridge, United Kingdom (A.P.); Roche pRED, Basel, Switzerland (C.R.); GlaxoSmithKline, Stevenage, United Kingdom (P.S.-S.); Genentech, San Francisco, California (D.Z.); and Takeda Development Center Americas, San Diego, California (M.Z.).

المصدر: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2023 Jul; Vol. 51 (7), pp. 792-803. Date of Electronic Publication: 2023 Apr 11.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: United States NLM ID: 9421550 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-009X (Electronic) Linking ISSN: 00909556 NLM ISO Abbreviation: Drug Metab Dispos Subsets: MEDLINE

مواضيع طبية MeSH: Drug Discovery* , Ubiquitin-Protein Ligases*, Humans ; Biological Availability ; Solubility

المؤلفون: Coe KJ; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.) kcoe2@its.jnj.com., Feinstein M; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.)., Higgins JW; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.)., Leung P; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.)., Scott BP; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.)., Skaptason J; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.)., Tam Y; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.)., Volak LP; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.)., Kinong J; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.)., Bittner A; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.)., McAllister H; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.)., Lim NM; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.)., Hack M; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.)., Koudriakova T; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.).

المصدر: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2022 Aug; Vol. 50 (8), pp. 1064-1076. Date of Electronic Publication: 2022 Jun 09.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: United States NLM ID: 9421550 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-009X (Electronic) Linking ISSN: 00909556 NLM ISO Abbreviation: Drug Metab Dispos Subsets: MEDLINE

مواضيع طبية MeSH: Cytochrome P-450 CYP1A1*/metabolism , Receptors, Aryl Hydrocarbon*/metabolism, Amines ; Animals ; Humans ; Pyrimidines/pharmacology ; Rats ; Thiazoles/pharmacology

المؤلفون: Petersson C; The Healthcare Business of Merck KGaA, Frankfurter Str. 250, Postcode D50/902, 64293, Darmstadt, Germany. carl.petersson@merckgroup.com., Zhou X; Eli Lilly and Company, Indianapolis, IN, USA., Berghausen J; Novartis, Basel, Switzerland., Cebrian D; GSK, Brentford, UK., Davies M; AstraZeneca, Cambridge, UK., DeMent K; Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA.; XinThera, Inc., San Diego, CA, USA., Eddershaw P; Vertex Pharmaceuticals Incorporated, Boston, MA, USA., Riedmaier AE; Bristol-Myers Squibb, New York, NY, USA., Leblanc AF; AbbVie Inc., North Chicago, IL, USA., Manveski N; F. Hoffman-La Roche Ltd., Basel, Switzerland., Marathe P; Agios Pharmaceuticals, Cambridge, MA, USA., Mavroudis PD; Sanofi, Paris, France., McDougall R; Alnylam Pharmaceuticals, Inc., Cambridge, MA, USA.; Repare Therapeutics, Quebec City, Canada., Parrott N; F. Hoffman-La Roche Ltd., Basel, Switzerland., Reichel A; Bayer AG, Leverkusen, Germany., Rotter C; Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA., Tess D; Pfizer, Inc., New York, NY, USA., Volak LP; Janssen Research and Development, LLC, Raritan, NJ, USA., Xiao G; Sunovion Pharmaceuticals, Inc., Marlborough, MA, USA., Yang Z; Bristol-Myers Squibb, New York, NY, USA., Baker J; Merck and Co., Inc, Kenilworth, NJ, USA.; Blueprint Medicines, Cambridge, MA, USA.

المصدر: The AAPS journal [AAPS J] 2022 Jul 19; Vol. 24 (5), pp. 85. Date of Electronic Publication: 2022 Jul 19.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: American Association of Pharmaceutical Scientists Country of Publication: United States NLM ID: 101223209 Publication Model: Electronic Cited Medium: Internet ISSN: 1550-7416 (Electronic) Linking ISSN: 15507416 NLM ISO Abbreviation: AAPS J Subsets: MEDLINE

مواضيع طبية MeSH: Drug Industry* , Models, Biological*, Humans ; Kinetics ; Pharmaceutical Preparations